The Selexys Pharmaceutical project is to be executed in Cytovance’s multi-product process development and cGMP production facility in Oklahoma City over the next 15 months. The 44,000sqft facility meets the latest international regulatory standards and is custom-designed for efficient and cost-effective production.
The project team will be composed of members of both Oklahoma City-based organizations working closely together.
Scott Rollins, president and CEO of Selexys, said: “Selexys is pleased to announce the selection of Cytovance Biologics as our contract manufacturer for our lead drug candidate for Crohn’s disease. Cytovance brings substantial expertise in biologics manufacturing that will serve to advance our lead drug candidate into clinical development.”